ES2149955T3 - Vesiculas con liberacion controlada de sustancias activas. - Google Patents

Vesiculas con liberacion controlada de sustancias activas.

Info

Publication number
ES2149955T3
ES2149955T3 ES95901208T ES95901208T ES2149955T3 ES 2149955 T3 ES2149955 T3 ES 2149955T3 ES 95901208 T ES95901208 T ES 95901208T ES 95901208 T ES95901208 T ES 95901208T ES 2149955 T3 ES2149955 T3 ES 2149955T3
Authority
ES
Spain
Prior art keywords
vesicles
controlled release
active substance
biologically active
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95901208T
Other languages
English (en)
Inventor
Mantripragada Sankaram
Sinil Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Skyepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22548158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2149955(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skyepharma Inc filed Critical Skyepharma Inc
Application granted granted Critical
Publication of ES2149955T3 publication Critical patent/ES2149955T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/08—Systemic pesticides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA COMPOSICION DE VESICULA DE MEMBRANA SINTETICA QUE CONTIENE AL MENOS UN AGENTE MODIFICANTE DEL INDICE DE LIBERACION, DISTINTO DE UN HIDROALIDO, Y AL MENOS UNA SUSTANCIA BIOLOGICAMENTE ACTIVA, TENIENDO LAS VESICULAS UNA DISTRIBUCION DE TAMAÑO DEFINIDO, AJUSTABLE AL TAMAÑO MEDIO, UN NUMERO Y TAMAÑO DE CAMARA INTERNA, Y UNA LIBERACION CONTROLADA DE LA SUSTANCIA BIOLOGICAMENTE ACTIVA. UN PROCEDIMIENTO PARA FABRICAR LA COMPOSICION CONTRIBUYE A MAXIMIZAR UN AGENTE MODIFICANTE DEL INDICE DE LIBERACION PARA PROLONGAR, SOSTENER Y CONTROLAR EL INDICE DE LIBERACION DE LAS VESICULAS DE LA SUSTANCIA BIOLOGICAMENTE ACTIVA A NIVELES TERAPEUTICOS, DESPUES DE LA ENCAPSULACION.
ES95901208T 1993-11-16 1994-11-10 Vesiculas con liberacion controlada de sustancias activas. Expired - Lifetime ES2149955T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15365793A 1993-11-16 1993-11-16

Publications (1)

Publication Number Publication Date
ES2149955T3 true ES2149955T3 (es) 2000-11-16

Family

ID=22548158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95901208T Expired - Lifetime ES2149955T3 (es) 1993-11-16 1994-11-10 Vesiculas con liberacion controlada de sustancias activas.

Country Status (25)

Country Link
US (1) US6132766A (es)
EP (1) EP0729351B1 (es)
JP (1) JP3002702B2 (es)
KR (1) KR100241300B1 (es)
CN (1) CN1099868C (es)
AT (1) ATE196248T1 (es)
AU (1) AU686277B2 (es)
BG (1) BG63146B1 (es)
BR (1) BR9408072A (es)
CA (1) CA2176712C (es)
DE (1) DE69425901T2 (es)
DK (1) DK0729351T3 (es)
ES (1) ES2149955T3 (es)
FI (1) FI115823B (es)
GR (1) GR3034954T3 (es)
HU (1) HUT75162A (es)
IL (1) IL111628A (es)
NO (1) NO304577B1 (es)
NZ (1) NZ276305A (es)
PL (1) PL314485A1 (es)
PT (1) PT729351E (es)
RO (1) RO116341B1 (es)
RU (1) RU2160093C2 (es)
WO (1) WO1995013796A1 (es)
ZA (1) ZA949063B (es)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2271388C (en) * 1996-09-13 2007-11-06 The School Of Pharmacy, University Of London Liposomes encapsulating polynucleotides operatively coding for immunogenic polypeptides
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
CA2269631C (en) * 1996-10-25 2008-03-25 Monsanto Company Composition and method for treating plants with exogenous chemicals
AU4998997A (en) 1996-10-25 1998-05-15 Monsanto Company Composition and method for treating plants with exogenous chemicals
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP1365028B1 (en) 1996-12-13 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Method for expression of PDGF or IGF proteins in yeast
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
CA2304096C (en) 1997-09-18 2003-09-09 Skyepharma Inc. Sustained-release liposomal anesthetic compositions
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
NZ504188A (en) 1997-11-14 2001-10-26 Skyepharma Inc Emulsification process for preparing multivesicular liposomes
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
EP2261346A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
JP2003524389A (ja) 1998-12-16 2003-08-19 カイロン コーポレイション ヒトサイクリン依存的キナーゼ（ｈＰＮＱＡＬＲＥ）
IL144561A0 (en) * 1999-01-25 2002-05-23 Optime Therapeutics Inc Liposome compositions and methods for treating pests utilizing the same
EP2278007B1 (en) 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CA2954411A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
DE60043197D1 (es) 1999-11-18 2009-12-03 Univ Kyoto
KR20090016517A (ko) 1999-12-23 2009-02-13 벨루스 헬스 (인터내셔널) 리미티드 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법
DK1897555T3 (da) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Kompletteret OMV-vaccine mod meningococcus
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ATE397094T1 (de) 2000-06-15 2008-06-15 Novartis Vaccines & Diagnostic Polynukleotide zur bestimmung von kolonkrebs
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
JP3966819B2 (ja) 2001-05-24 2007-08-29 キム，スーギョン 毛嚢に存在する新規の第２ケラチノサイト成長因子類似体
US7498407B2 (en) 2001-11-09 2009-03-03 Georgetown University Vascular endothelial cell growth inhibitor, VEGI-192a
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
EP1572933A4 (en) 2002-02-13 2007-09-05 Univ Duke MODULATION OF IMMUNE RESPONSE BY POLYPEPTIDES OF RESPONSE TO STRESS BINDING TO NON PEPTIDES
FR2836043B1 (fr) * 2002-02-15 2004-06-04 Inst Nat Sante Rech Med Vesicules lipidiques, preparation et utilisations
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
EP1501855A4 (en) 2002-03-21 2006-02-22 Sagres Discovery Inc NEW COMPOSITIONS AND METHODS FOR CANCER
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP2302039A1 (en) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virus-like particles comprising HML-2 gag polypeptide
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1665487A (zh) * 2002-07-03 2005-09-07 埃弗顿有限公司 脂质体疫苗
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2505520C (en) * 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
SI1575517T1 (sl) 2002-12-24 2012-06-29 Rinat Neuroscience Corp Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1592708A2 (en) 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
ATE491444T1 (de) 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005053605A2 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Therapeutic liposomes
BRPI0417270A (pt) 2003-12-23 2007-03-27 Rinat Neuroscience Corp anticorpos agonistas antitrkc e métodos para utilização dos mesmos
ES2584867T3 (es) * 2004-01-12 2016-09-29 Mannkind Corporation Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
US7223562B2 (en) 2004-03-31 2007-05-29 New York University Compositions for controlling hair growth
ES2338344T3 (es) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
PT1789593T (pt) 2004-07-09 2017-04-24 Henry M Jackson Found Advancement Military Medicine Inc Formas solúveis de glicoproteína g de vírus hendra
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP5042828B2 (ja) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
EP1827385B1 (en) 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
EP1910557A2 (en) 2005-04-07 2008-04-16 Chiron Corporation Cancer-related genes
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
HUE028623T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
EP2012817A2 (en) 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
CA2652703C (en) 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CA2684321A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity
AP2009005028A0 (en) 2007-04-10 2009-12-31 Univ Tulane Soluble and membrane-anchored forms of lassa virussubunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
KR20130087632A (ko) 2007-12-17 2013-08-06 화이자 리미티드 간질성 방광염의 치료
NZ585959A (en) 2007-12-18 2012-09-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009149418A2 (en) * 2008-06-06 2009-12-10 Asuragen, Inc. Novel compositions for the in vivo delivery of rnai agents
ES2570400T3 (es) 2008-06-13 2016-05-18 Mannkind Corp Un inhalador de polvo seco y un sistema para el suministro de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US20110250266A1 (en) * 2008-10-07 2011-10-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
JP2012532626A (ja) 2009-07-16 2012-12-20 ノバルティス アーゲー 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
KR20120138241A (ko) 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
ES2770575T3 (es) * 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2630953B1 (en) * 2010-12-27 2017-08-09 Terumo Kabushiki Kaisha Liposome composition and process for production thereof
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
RU2480479C1 (ru) * 2011-11-01 2013-04-27 Елена Викторовна Свирщевская Гетерологичный пептидный мини-антиген в составе полимерной частицы для создания противоаллергенной вакцины
EP2776470A2 (en) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
AU2012356206A1 (en) 2011-12-22 2014-06-26 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
RU2678433C2 (ru) 2012-05-10 2019-01-29 Пейнреформ Лтд. Депо-составы гидрофобного активного ингредиента и способы их получения
FR2991196B1 (fr) * 2012-05-29 2014-06-27 Capsum Nanoparticules ciblantes pour une application biologique
JP5918909B2 (ja) 2012-06-25 2016-05-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
WO2014008263A2 (en) 2012-07-02 2014-01-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus and methods of use
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
KR20160029731A (ko) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
EP2970502A4 (en) 2013-03-15 2016-11-30 Dyax Corp ANTI-PLASMA KALLIKREIN ANTIBODY
EP3842443A1 (en) 2013-03-15 2021-06-30 Cerenis Therapeutics Holding SA Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
CN110237270A (zh) 2013-03-15 2019-09-17 洛马林达大学 自身免疫性疾病的治疗
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2015015339A (es) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
CN113683695A (zh) 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
CA3056647A1 (en) 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015089321A2 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
EP3936115A1 (en) 2014-04-21 2022-01-12 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
SI3134070T1 (sl) 2014-04-21 2021-03-31 Heron Therapeutics, Inc. Sestave poliortoestra in pomožne snovi iz organske kisline
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3142656B1 (en) * 2015-01-21 2018-10-17 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
SG10201912823PA (en) 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
KR20180096567A (ko) 2015-07-21 2018-08-29 다이액스 코포레이션 Xiia 인자의 단일클론 항체 저해제
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
MY195443A (en) 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
IL258121B2 (en) 2015-09-15 2024-01-01 Scholar Rock Inc Antipro/latent myostatin antibodies and their uses
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
JP2019506398A (ja) 2016-01-21 2019-03-07 ファイザー・インク 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
MX2019010458A (es) 2017-03-03 2020-01-20 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos.
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
AU2018275359C1 (en) 2017-06-02 2022-02-03 Pfizer Inc. Antibodies specific for FLT3 and their uses
US10650911B2 (en) 2017-06-13 2020-05-12 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
EP3651799A1 (en) 2017-07-13 2020-05-20 Massachusetts Institute of Technology Targeting the hdac2-sp3 complex to enhance synaptic function
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
BR112020015641A2 (pt) 2018-02-01 2021-01-05 Pfizer Inc. Anticorpos específicos para cd70 e seus usos
WO2019152742A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
US11059876B2 (en) 2018-02-28 2021-07-13 Pfizer Inc. IL-15 variants and uses thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
JP7384835B2 (ja) 2018-05-23 2023-11-21 ファイザー・インク Ｃｄ３に特異的な抗体及びその使用
AU2020212563A1 (en) 2019-01-23 2021-09-16 New York University Antibodies specific to delta 1 chain of T cell receptor
CA3146077A1 (en) 2019-07-03 2021-02-18 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
US20220273568A1 (en) * 2019-07-12 2022-09-01 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of dexmedetomidine
CN114144177A (zh) * 2019-08-01 2022-03-04 英凯达治疗公司 抗心律失常制剂
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
EP4041308A1 (en) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240092935A1 (en) 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
WO2021151079A1 (en) 2020-01-24 2021-07-29 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
EP4146688A1 (en) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Mask peptides and masked anti-ptk7 antibodies comprising such
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
CA3190513A1 (en) 2020-09-03 2022-03-10 Jeffrey S. Bartlett Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4330969A1 (en) 2021-04-29 2024-03-06 BostonGene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
WO2023012627A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
US20230245479A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
KR20240139082A (ko) 2022-02-02 2024-09-20 화이자 인코포레이티드 시스테인 프로토트로피
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
CN115486539A (zh) * 2022-09-14 2022-12-20 厦门遇见今生生物科技有限公司 具有抗衰老及端粒延长的草药提取物仿生膜及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (es) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (es) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
FI860430A0 (fi) * 1986-01-29 1986-01-29 Imatran Voima Oy Foerfarande och anordning foer utnyttjande av vaermeenergi som frigoers i kylprocess.
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
EP0500143A3 (en) * 1986-12-23 1993-03-03 The Liposome Company, Inc. Pharmaceutical composition comprising an aminoglycoside phosphate
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
IN168530B (es) * 1987-11-06 1991-04-20 Lyphomed Inc
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds

Also Published As

Publication number Publication date
ZA949063B (en) 1995-09-13
US6132766A (en) 2000-10-17
EP0729351A1 (en) 1996-09-04
BG100596A (bg) 1996-12-31
HUT75162A (en) 1997-04-28
IL111628A0 (en) 1995-01-24
AU686277B2 (en) 1998-02-05
FI115823B (fi) 2005-07-29
GR3034954T3 (en) 2001-02-28
DE69425901D1 (de) 2000-10-19
EP0729351B1 (en) 2000-09-13
PL314485A1 (en) 1996-09-16
BR9408072A (pt) 1997-08-12
CA2176712A1 (en) 1995-05-26
DK0729351T3 (da) 2000-10-16
JP3002702B2 (ja) 2000-01-24
IL111628A (en) 2002-08-14
ATE196248T1 (de) 2000-09-15
NO962024D0 (no) 1996-05-15
BG63146B1 (bg) 2001-05-31
RU2160093C2 (ru) 2000-12-10
NO962024L (no) 1996-07-09
FI962048A0 (fi) 1996-05-14
JPH09505301A (ja) 1997-05-27
CN1140989A (zh) 1997-01-22
PT729351E (pt) 2000-12-29
NO304577B1 (no) 1999-01-18
CA2176712C (en) 2000-05-23
NZ276305A (en) 1997-10-24
HU9601316D0 (en) 1996-07-29
WO1995013796A1 (en) 1995-05-26
KR100241300B1 (ko) 2000-03-02
FI962048A (fi) 1996-07-15
EP0729351A4 (en) 1998-02-04
RO116341B1 (ro) 2001-01-30
AU1053595A (en) 1995-06-06
DE69425901T2 (de) 2001-04-26
CN1099868C (zh) 2003-01-29

Similar Documents

Publication Publication Date Title
ES2149955T3 (es) Vesiculas con liberacion controlada de sustancias activas.
MX9701856A (es) Preparacion de liposomas multi-vesiculares para la liberacion controlada de agentes activos.
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
TW358031B (en) Drug delivery system for 2 or more active substances
BR8801242A (pt) Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao
GEP20022707B (en) Biodegrading Macromers for the Controlled Release of Biologically Active Substances
PL323152A1 (en) Derivatives of 1,3-propanodiole as biologically active compounds
MA26466A1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation .
HK1001860A1 (en) I-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
HUP9600116A3 (en) Fungicidal composition containing benzophenone, process for preparation of the active ingredients and method for the control of fungi.
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
IL105942A0 (en) Biologically active eburnamenine derivatives,their preparation and pharmaceutical compositions containing them
HU9202107D0 (en) Pesticide and plant growth regulating preparatives containing 3,5-dioxo-3,4,5,6-tetrahydro-oxazines as active substance and method for producing the active substances
IL117943A (en) Dihalopropene compounds and insecticides containing them as active ingredients
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
ZA968230B (en) Administration of biologically active material
DE59607949D1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
SI0808158T1 (en) Medicament form for the delivery of active substances to wounds
BG98019A (en) Method for the preparation of biologically active substances
AU2799995A (en) Sex reversion by altering biologically active amount of acat
CS420088A1 (en) 1-/4-/3-alkoxy-3-alkyl-2-halogenbutoxy/phenyl/alkylester-3/2,2-di halogenethenyl/-2,2-dimethylcyclopropancarboxyl acids as biologically active substance and method of its preparation
HU902252D0 (en) Insecticide preparatives containing phenyl-pyrimidinone derivatives as active substance and process for producing the active substance
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 729351

Country of ref document: ES